FDA has approved imaging system to help detect cervical cancer.
BD says reducing false-negative findings and interpretation errors is the system's goal. That's accomplished through "state-of-the-art" guided screening technology for rapidly relocating the fields of view that the system identifies as likeliest to contain cells of interest.
For more information, visit the company's Web site at http://www.bd.com/.
FDA grants 510(k) clearance to chemiluminescence-based immunoassay
Published: January 10th 2025 | Updated: January 10th 2025The automated chemiluminescence-based immunoassay has received clearance for free testosterone, providing enhanced diagnostic options to a multitude of conditions.
Read More